Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Perez-Moreno P, Brambilla E, Thomas R, et al. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012;18(9):2443–2451. doi: 10.1158/1078-0432.CCR-11-2370.
   PubMed Web of Science ®Google Scholar
• Bruno R, Alì G, Poma AM, et al. Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review. Precis Cancer Med. 2021;4:14–14. doi: 10.21037/pcm-20-72.
   Google Scholar
• Edsjö A, Holmquist L, Geoerger B, et al. Precision cancer medicine: concepts, current practice, and future developments. J Intern Med. 2023;294(4):455–481. doi: 10.1111/joim.13709.
   PubMed Web of Science ®Google Scholar
• Mehmood S, Aslam S, Dilshad E, et al. Transforming diagnosis and therapeutics using cancer genomics. Cancer Treat Res. 2023;185:15–47. doi: 10.1007/978-3-031-27156-4_2.
   PubMedGoogle Scholar
• Krpina K, Vranić S, Tomić K, et al. Small cell lung carcinoma: current diagnosis, biomarkers, and treatment options with future perspectives. Biomedicines. 2023;11(7):1982. doi: 10.3390/biomedicines11071982.
   PubMed Web of Science ®Google Scholar
• Ding XL, Su YG, Yu L, et al. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC). World J Surg Oncol. 2022;20(1):54. doi: 10.1186/s12957-022-02528-y.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Updated non-small cell lung cancer version 5.2023; 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
   Google Scholar
• Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339–357. doi: 10.1016/j.annonc.2022.12.009.
   PubMedGoogle Scholar
• Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531–542. doi: 10.1200/EDBK_237863.
   PubMedGoogle Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, The International Association for the study of lung cancer, and the association for molecular pathology. Arch Pathol Lab Med. 2018;142(3):321–346. doi: 10.5858/arpa.2017-0388-CP.
   PubMed Web of Science ®Google Scholar
• Vranic S, Gatalica Z. PD-L1 testing by immunohistochemistry in immuno-oncology. Biomol Biomed. 2023;23(1):15–25. doi: 10.17305/bjbms.2022.7953.
   PubMedGoogle Scholar
• Hirsch FR, Bunn PA.Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009;10(5):432–433. doi: 10.1016/S1470-2045(09)70110-X.
   PubMed Web of Science ®Google Scholar
• Koulouris A, Tsagkaris C, Corriero AC, et al. Resistance to TKIs in EGFR-Mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. Cancers. 2022;14(14):3337. doi: 10.3390/cancers14143337.
   PubMed Web of Science ®Google Scholar
• Sivakumar S, Moore JA, Montesion M, et al. Integrative analysis of a large Real-World cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation. Cancer Discov. 2023;13(7):1572–1591. doi: 10.1158/2159-8290.CD-22-0620.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.
   PubMed Web of Science ®Google Scholar
• Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-Mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37(4):278–285. doi: 10.1200/JCO.18.01585.
   PubMed Web of Science ®Google Scholar
• Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165-72–e172. doi: 10.1016/S1470-2045(14)71180-5.
   PubMed Web of Science ®Google Scholar
• Kolesar J, Peh S, Thomas L, et al. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Mol Cancer. 2022;21(1):61. doi: 10.1186/s12943-022-01534-8.
   PubMed Web of Science ®Google Scholar
• Reita D, Pabst L, Pencreach E, et al. Molecular mechanism of EGFR-TKI resistance in EGFR-Mutated non-small cell lung cancer: application to biological diagnostic and monitoring. Cancers . 2021;13(19):4926. doi: 10.3390/cancers13194926.
   PubMed Web of Science ®Google Scholar
• Baine MK, Hsieh MS, Lai WV, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15(12):1823–1835. doi: 10.1016/j.jtho.2020.09.009.
   PubMed Web of Science ®Google Scholar
• Chan JM, Quintanal-Villalonga A, Gao VR, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39(11):1479–1496 e18. doi: 10.1016/j.ccell.2021.09.008.
   PubMed Web of Science ®Google Scholar
• Testa U, Castelli G, Pelosi E. Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers. 2018;10(8):248. doi: 10.3390/cancers10080248.
   PubMed Web of Science ®Google Scholar
• Shaurova T, Zhang L, Goodrich DW, et al. Understanding lineage plasticity as a path to targeted therapy failure in EGFR-mutant non-small cell lung cancer. Front Genet. 2020;11:281. doi: 10.3389/fgene.2020.00281.
   PubMed Web of Science ®Google Scholar
• Xue W, Cai L, Li S, et al. WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice. Discov Oncol. 2023;14(1):136. doi: 10.1007/s12672-023-00739-7.
   PubMedGoogle Scholar
• Sharif A, Shaji A, Chammaa M, et al. Notch transduction in non-small cell lung cancer. Int J Mol Sci. 2020;21(16):5691. doi: 10.3390/ijms21165691.
   PubMed Web of Science ®Google Scholar
• Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. doi: 10.1186/s12943-023-01740-y.
   PubMed Web of Science ®Google Scholar
• Imakita T, Fujita K, Kanai O, et al. Small cell lung cancer transformation during immunotherapy with nivolumab: a case report. Respir Med Case Rep. 2017;21:52–55. doi: 10.1016/j.rmcr.2017.03.019.
   PubMed Web of Science ®Google Scholar
• Imakita T, Fujita K, Kanai O, et al. Small cell transformation of non-small cell lung cancer under immunotherapy: case series and literature review. Thorac Cancer. 2021;12(22):3062–3067. doi: 10.1111/1759-7714.14180.
   PubMed Web of Science ®Google Scholar
• Yin X, Li Y, Wang H, et al. Small cell lung cancer transformation: from pathogenesis to treatment. Semin Cancer Biol. 2022;86(Pt 2):595–606. doi: 10.1016/j.semcancer.2022.03.006.
   PubMedGoogle Scholar
• Chen Y, He M, Dai Z, et al. Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment. Front Oncol. 2023;13:1308313. doi: 10.3389/fonc.2023.1308313.
   PubMed Web of Science ®Google Scholar
• Mambetsariev I, Arvanitis L, Fricke J, et al. Small cell lung cancer transformation following treatment in EGFR-mutated non-small cell lung cancer. J Clin Med. 2022;11(5):1429.
   Web of Science ®Google Scholar
• Yu L, Bazhenova L, Gold K, et al. Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. Transl Lung Cancer Res. 2022;11(3):452–461. doi: 10.21037/tlcr-21-665.
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Akamatsu H, Morimoto T, et al. Histologic transformation of epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022;166:41–50. doi: 10.1016/j.ejca.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Jin CB, Yang L. Histological transformation of non-small cell lung cancer: clinical analysis of nine cases. World J Clin Cases. 2021;9(18):4617–4626. doi: 10.12998/wjcc.v9.i18.4617.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu C, Chen H, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: a multicenter retrospective study. Lung Cancer. 2021;155:20–27. doi: 10.1016/j.lungcan.2021.03.006.
   PubMed Web of Science ®Google Scholar
• Wang S, Xie T, Hao X, et al. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thorac Cancer. 2021;12(19):2585–2593. doi: 10.1111/1759-7714.14144.
   PubMed Web of Science ®Google Scholar
• Bai W, Zhen C, Zhang R, et al. Clinicopathological features of patients with transformation from EGFR mutant lung adenocarcinoma to small cell lung cancer. Transl Cancer Res. 2021;10(8):3694–3704. doi: 10.21037/tcr-21-653.
   PubMed Web of Science ®Google Scholar
• Xie T, Li Y, Ying J, et al. Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). Transl Lung Cancer Res. 2020;9(6):2428–2439. doi: 10.21037/tlcr-20-1278.
   PubMed Web of Science ®Google Scholar
• Mu Y, Hao X, Xing P, et al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. J Cancer Res Clin Oncol. 2020;146(9):2427–2433. doi: 10.1007/s00432-020-03239-1.
   PubMed Web of Science ®Google Scholar
• Vendrell JA, Quantin X, Serre I, et al. Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment. Ther Adv Med Oncol. 2020;12:1758835920974192. doi: 10.1177/1758835920974192.
   Web of Science ®Google Scholar
• Zeng L, Xiao L, Jiang W, et al. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a real world population. Lung Cancer. 2020;141:82–88. doi: 10.1016/j.lungcan.2020.01.009.
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26(11):2654–2663. doi: 10.1158/1078-0432.CCR-19-3563.
   PubMed Web of Science ®Google Scholar
• Ferrer L, Giaj Levra M, Brevet M, et al. A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics. J Thorac Oncol. 2019;14(1):130–134. doi: 10.1016/j.jtho.2018.08.2028.
   PubMed Web of Science ®Google Scholar
• Iacono D, Osman GA, Migliorino MR, et al. Intrapatient molecular and histologic heterogeneity after first-generation or second-generation TKI therapy of NSCLC patients: potential clinical impact on subsequent third-generation TKI treatment. Am J Clin Oncol. 2019;42(11):845–850. doi: 10.1097/COC.0000000000000615.
   PubMed Web of Science ®Google Scholar
• Yang H, Liu L, Zhou C, et al. The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer. Medicine. 2019;98(12):e14893.). doi: 10.1097/MD.0000000000014893.
   PubMed Web of Science ®Google Scholar
• Lee K, Kim Y, Jung HA, et al. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer. 2019;130:87–92. doi: 10.1016/j.lungcan.2019.01.012.
   PubMed Web of Science ®Google Scholar
• Mehlman C, Cadranel J, Rousseau-Bussac G, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019;137:149–156. doi: 10.1016/j.lungcan.2019.09.019.
   PubMed Web of Science ®Google Scholar
• Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784–1793. doi: 10.1016/j.jtho.2019.06.002.
   PubMed Web of Science ®Google Scholar
• Ahmed T, Vial MR, Ost D, et al. Non-small cell lung cancer transdifferentiation into small cell lung cancer: a case series. Lung Cancer. 2018;122:220–223. doi: 10.1016/j.lungcan.2018.06.024.
   PubMed Web of Science ®Google Scholar
• Minari R, Bordi P, Del Re M, et al. Primary resistance to osimertinib due to SCLC transformation: issue of T790M determination on liquid re-biopsy. Lung Cancer. 2018;115:21–27. doi: 10.1016/j.lungcan.2017.11.011.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-Positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4(11):1527–1534. doi: 10.1001/jamaoncol.2018.2969.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8(12):1529–1539. doi: 10.1158/2159-8290.CD-18-1022.
   PubMed Web of Science ®Google Scholar
• Lin CC, Shih JY, Yu CJ, et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018;6(2):107–116. doi: 10.1016/S2213-2600(17)30480-0.
   PubMed Web of Science ®Google Scholar
• Lee JK, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol. 2017;35(26):3065–3074. doi: 10.1200/JCO.2016.71.9096.
   PubMed Web of Science ®Google Scholar
• Ahn S, Hwang SH, Han J, et al. Transformation to small cell lung cancer of pulmonary adenocarcinoma: clinicopathologic analysis of six cases. J Pathol Transl Med. 2016;50(4):258–263. doi: 10.4132/jptm.2016.04.19.
   PubMed Web of Science ®Google Scholar
• Nosaki K, Satouchi M, Kurata T, et al. Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study. Lung Cancer. 2016;101:1–8. doi: 10.1016/j.lungcan.2016.07.007.
   PubMed Web of Science ®Google Scholar
• Norkowski E, Ghigna MR, Lacroix L, et al. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology. J Thorac Oncol. 2013;8(10):1265–1271. doi: 10.1097/JTO.0b013e3182a407fa.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi: 10.1158/1078-0432.CCR-12-2246.
   PubMed Web of Science ®Google Scholar
• Wang D, Ye W, Chen D, et al. Transformation of lung squamous cell carcinoma to small cell lung cancer after immunotherapy resistance: a case report. Cancer Manag Res. 2023;15:803–808. doi: 10.2147/CMAR.S420485.
   PubMed Web of Science ®Google Scholar
• Liu H, Chen LH, Zhang ZH, et al. Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: a report of two cases. Front Oncol. 2022;12:1022705. doi: 10.3389/fonc.2022.1022705.
   PubMed Web of Science ®Google Scholar
• Arakawa S, Yoshida T, Shirasawa M, et al. RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient. Lung Cancer. 2021;151:101–103. doi: 10.1016/j.lungcan.2020.11.016.
   PubMed Web of Science ®Google Scholar
• Sehgal K, Varkaris A, Viray H, et al. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer. 2020;8(1):e000697. doi: 10.1136/jitc-2020-000697.
   PubMed Web of Science ®Google Scholar
• Si X, You Y, Zhang X, et al. Histologic transformation of lung cancer during pembrolizumab therapy: a case report. Thorac Cancer. 2020;11(3):793–796. doi: 10.1111/1759-7714.13312.
   PubMed Web of Science ®Google Scholar
• Miura N, Matsubara T, Takamori S, et al. Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report. Oxf Med Case Reports. 2020;2020(4):omaa026.
   PubMedGoogle Scholar
• Bar J, Ofek E, Barshack I, et al. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer. 2019;138:109–115. doi: 10.1016/j.lungcan.2019.09.025.
   PubMed Web of Science ®Google Scholar
• Okeya K, Kawagishi Y, Muranaka E, et al. Hyperprogressive disease in lung cancer with transformation of adenocarcinoma to small-cell carcinoma during pembrolizumab therapy. Intern Med. 2019;58(22):3295–3298. doi: 10.2169/internalmedicine.2892-19.
   PubMed Web of Science ®Google Scholar
• Iams WT, Beckermann KE, Almodovar K, et al. Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS-Mutant lung adenocarcinoma: a report of two cases. J Thorac Oncol. 2019;14(3):e45–e48. doi: 10.1016/j.jtho.2018.11.031.
   PubMed Web of Science ®Google Scholar
• Abdallah N, Nagasaka M, Abdulfatah E, et al. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer. 2018;9:85–90. doi: 10.2147/LCTT.S173724.
   PubMedGoogle Scholar
• Zeng J, Ding X, Ding J, et al. Histological transformation into SCLC: an important resistance mechanism of NSCLC upon immunotherapy. Front Immunol. 2023;14:1275957. doi: 10.3389/fimmu.2023.1275957.
   PubMed Web of Science ®Google Scholar
• Roca E, Gurizzan C, Amoroso V, et al. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: a systematic review and pooled analysis. Cancer Treat Rev. 2017;59:117–122. doi: 10.1016/j.ctrv.2017.07.007.
   PubMed Web of Science ®Google Scholar
• Guleria P, Kumar S, Malik PS, et al. PD-L1 expression in small cell and large cell neuroendocrine carcinomas of lung: an immunohistochemical study with review of literature. Pathol Oncol Res. 2020;26(4):2363–2370. doi: 10.1007/s12253-020-00832-0.
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi: 10.1158/2159-8290.CD-21-1059.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Saltos A, Shaw AT, et al. Pathology issues in thoracic oncology: histologic characterization and tissue/plasma genotyping may resolve diagnostic dilemmas. Am Soc Clin Oncol Educ Book. 2017;37(37):619–629. doi: 10.1200/EDBK_175197.
   PubMedGoogle Scholar
• Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6(1):6377. doi: 10.1038/ncomms7377.
   PubMedGoogle Scholar